VOR insider ownership: who sold, why, and what they still hold

What stands out

Outside holder RA CAPITAL MANAGEMENT, L.P., a 10% owner and not part of management, sold $83.1M of stock.Largest sale, Apr 6, 2026

No officer or director sold shares in this period. 20 are left out

Left out: Sandesh Mahatme, Qing Zuraw, Robert Ang, Jeremy Sokolove, Tirtha Chakraborty, Han Choi, Daniella Beckman, David Lubner, Sven Lundberg, Matthew Patterson, Joshua Resnick, Fouad Namouni, Erez Kalir, Jean-Paul Kress, Alexander Cumbo, Michel Detheux, Sarah Reed, Andrew Levin, Wouter Joustra and David Zaccardelli (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days.

Outside holders, reported separately

RA CAPITAL MANAGEMENT, L.P. sold $83.1M and Reprogrammed Interchange LLC sold $4.5M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Vor Biopharma Inc. CEO selling stock?

No. Robert Ang reported no open-market sales in the past 12 months.

Are any Vor Biopharma Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold0 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan

Outside holder, reported separately: TCG Crossover GP II, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (a 10% owner, not part of management). Sold $83.1M (4.21M shares) from Oct 15, 2025 to Jul 16, 2026. Latest filing

Outside holder, reported separately: Reprogrammed Interchange LLC (a 10% owner, not part of management). Sold $4.5M (145K shares) from Oct 14, 2025 to Oct 21, 2025. Latest filing

The full ownership picture0 of 20 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Sandesh Mahatme

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Sandesh Mahatme are complete.

CFO

n/a

Vesting, gifts, unvested awards and holding lines for Sandesh Mahatme

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandesh Mahatme are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,388,274	$17.80	Dec 4, 2035	$2.7M

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Qing Zuraw

Chief Development Officer

n/a

Vesting, gifts, unvested awards and holding lines for Qing Zuraw

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Qing Zuraw are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
218,652	$47.60	Jul 16, 2035	$0
218,652	$8.18	Jul 16, 2035	$2.5M

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Robert Ang

President and CEO, Director

n/a

Vesting, gifts, unvested awards and holding lines for Robert Ang

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Ang are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,365	$26.80	Mar 9, 2030	$0
32,604	$26.80	Aug 20, 2030	$0
2,553	$26.80	Feb 4, 2031	$0
18,800	$26.80	Jan 31, 2032	$0
8,625	$26.80	Aug 31, 2032	$0
12,875	$26.80	Feb 5, 2033	$0
23,500	$26.80	Jan 28, 2034	$0
41,250	$26.80	Feb 2, 2035	$0

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Jeremy Sokolove

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Jeremy Sokolove

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeremy Sokolove are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
130,100	$8.18	Oct 31, 2035	$1.5M

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Tirtha Chakraborty

Chief Sci Off & Head Tech Ops

n/a

Vesting, gifts, unvested awards and holding lines for Tirtha Chakraborty

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tirtha Chakraborty are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,440	$26.80	Sep 24, 2029	$0
1,221	$26.80	Mar 9, 2030	$0
3,533	$26.80	Aug 20, 2030	$0
6,066	$26.80	Nov 17, 2030	$0
5,050	$26.80	Jan 31, 2032	$0
3,800	$26.80	Aug 31, 2032	$0
4,775	$26.80	Feb 5, 2033	$0
5,375	$26.80	Jan 28, 2034	$0
15,750	$26.80	Feb 2, 2035	$0

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Han Choi

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Han Choi are complete.

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Han Choi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Han Choi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,000	$14.00	Sep 29, 2034	$115K
15,750	$26.80	Feb 2, 2035	$0

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Daniella Beckman

Director

n/a

Vesting, gifts, unvested awards and holding lines for Daniella Beckman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniella Beckman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,500	$32.20	May 22, 2034	$0
1,500	$3.74	May 21, 2035	$24K
53,283	$14.09	Jun 10, 2036	$302K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

David Lubner

Director

n/a

Vesting, gifts, unvested awards and holding lines for David Lubner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Lubner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,500	$32.20	May 22, 2034	$0
1,500	$3.74	May 21, 2035	$24K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Sven Lundberg

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sven Lundberg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sven Lundberg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,500	$32.20	May 22, 2034	$0
1,500	$3.74	May 21, 2035	$24K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Matthew Patterson

Director

n/a

Vesting, gifts, unvested awards and holding lines for Matthew Patterson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matthew Patterson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,500	$32.20	May 22, 2034	$0
1,500	$3.74	May 21, 2035	$24K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Joshua Resnick

Director

n/a

Vesting, gifts, unvested awards and holding lines for Joshua Resnick

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joshua Resnick are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,500	$32.20	May 22, 2034	$0
1,500	$3.74	May 21, 2035	$24K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Fouad Namouni

Director

n/a

Vesting, gifts, unvested awards and holding lines for Fouad Namouni

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Fouad Namouni are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$34.40	Apr 29, 2034	$0
1,500	$32.20	May 22, 2034	$0
1,500	$3.74	May 21, 2035	$24K
56,549	$14.09	Jun 10, 2036	$320K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Erez Kalir

Director

n/a

Vesting, gifts, unvested awards and holding lines for Erez Kalir

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Erez Kalir are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$34.80	Jan 5, 2035	$0
1,500	$3.74	May 21, 2035	$24K
57,162	$14.09	Jun 10, 2036	$324K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Jean-Paul Kress

CEO and Chairman, Director

n/a

Vesting, gifts, unvested awards and holding lines for Jean-Paul Kress

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jean-Paul Kress are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,164,832	$17.80	Jun 25, 2035	$8.1M
4,164,831	$8.18	Jun 25, 2035	$48.2M

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Alexander Cumbo

Director

n/a

Vesting, gifts, unvested awards and holding lines for Alexander Cumbo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alexander Cumbo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$42.40	Jul 15, 2035	$0
56,345	$14.09	Jun 10, 2036	$319K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Michel Detheux

Director

n/a

Vesting, gifts, unvested awards and holding lines for Michel Detheux

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michel Detheux are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$42.40	Jul 15, 2035	$0
57,162	$14.09	Jun 10, 2036	$324K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Sarah Reed

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sarah Reed

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sarah Reed are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$39.60	Sep 7, 2035	$0

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Andrew Levin

Director

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Levin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Levin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$12.80	Dec 17, 2035	$21K
57,162	$14.09	Jun 10, 2036	$324K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Wouter Joustra

Director

n/a

Vesting, gifts, unvested awards and holding lines for Wouter Joustra

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Wouter Joustra are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,000	$12.80	Dec 17, 2035	$21K
57,162	$14.09	Jun 10, 2036	$324K

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

David Zaccardelli

Director

n/a

Vesting, gifts, unvested awards and holding lines for David Zaccardelli

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Zaccardelli are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
42,658	$20.10	Jul 6, 2036	$0

Estimate: options held × ($19.75 − strike price), using the most recent insider trade price on Form 4 (Jul 16, 2026), not a market close.

Holdings and share of stake for Vor Biopharma Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

Is this normal? Selling year by year4 earlier years to compare with

Less than usual: no sales, against a 4-year average of 372 shares a year. 0 insiders sold; the average is 0 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	0	0	$0
Oct 13, 2025 1 year earlier	756	1	$20K
Oct 13, 2024 2 years earlier	732	1	$20K
Oct 14, 2023 3 years earlier	0	0	$0
Oct 14, 2022 4 years earlier	0	0	$0
Oct 14, 2021 5 years earlier · filings don't cover the whole year	n/a	n/a	n/a

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty20 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Vor Biopharma Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology211 filings on record, 35 filed in the 12-month period, and how we read them

All 211 Forms 3, 4 and 5 on record for Vor Biopharma Inc. (SEC CIK 1817229), filed from Feb 4, 2021 to Oct 5, 2026; 35 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Probable 1-for-20 stock split on or before Sep 18, 2025 (split date stated in a footnote). Splits aren't reported as transactions; 4 holding lines changed by exactly this ratio, so earlier share counts are restated.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (10)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Eyal Attar	Feb 18, 2025	6,331 shares, last reported balance as of Feb 13, 2025
Amy Quinlan	Nov 8, 2024	2,516 shares, last reported balance as of Nov 6, 2024
Nathan Jorgensen	May 7, 2024	9,470 shares, last reported balance as of May 6, 2024
Kush Parmar	Jun 16, 2022	No balance on record
Kush Parmar	Jun 16, 2022	318,086 shares, last reported balance as of Nov 16, 2021
Christopher Slapak	Feb 3, 2022	No balance on record
5AM Ventures VI, L.P.	Nov 18, 2021	318,086 shares, last reported balance as of Nov 16, 2021
Alexandria Venture Investments, LLC	Feb 9, 2021	14,140 shares, last reported balance as of Feb 9, 2021
Sadik Kassim	Feb 4, 2021	No balance on record
PureTech Health LLC	Feb 4, 2021	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

No officer or director has bought or sold Vor Biopharma Inc. stock in the past 12 months

What stands out

Recent activity

Outside holders, reported separately

Common questions

Is the Vor Biopharma Inc. CEO selling stock?

Are any Vor Biopharma Inc. insiders buying?

The evidence